Re: The crick didn’t rise, here’s the presentation, finally!
in response to
by
posted on
Oct 31, 2023 01:04PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Hi Jonzo,
I understand & repect the doubt & lack of trust with management/CEO etc. I've been one of the biggest critics of this fella.
It appears different this time with such a Huge company involved. Having said that I'm left with many questions & have reached out to Zenith IR with 3 emails this week asking for some clarity given the shortest & much lacking of any real detail.
this was the first one I sent below as I'm trying to wrap my head around just what the deal/cost is, if in fact Cencora has been working with Zen for 2-3 months , what's the trade off? Is this just censora doing DD prior to Cencora possibly pulling the trigger or what?? I followed up almost begging for more insight along with a few more comments- nothing back yet - I'll post if anything. This is where I start to fall back into you camp along with the other's who agree with you.
"What is the cost to Zenith in regards to Cencora advising them on development ,market etc? If they have been helping guide Zenith in these areas there must be a cost involved/trade off or sorts?
Need more details/understanding on this arrangement please.
Regards,
xxxx"